SCHEMBL1048864

SCHEMBL1048864

Cc1cccc(-c2cc3cc[nH]c(=O)c3c(Nc3ccc(-c4ccc(N5CCNCC5)nc4)c(C)c3)n2)n1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ZAP70 P43403 18/20 0.50
KCNH2 Q12809 1/20 0.48
CACNA1C Q13936 1/20 0.48
ASIC3 Q9UHC3 1/20 0.48
MAP3K11 Q16584 1/20 0.38
PRKD3 O94806 1/20 0.37
EGFR P00533 1/20 0.37
PRKCG P05129 1/20 0.37
PRKCB P05771 1/20 0.37
LCK P06239 1/20 0.37
PRKCA P17252 1/20 0.37
PRKCH P24723 1/20 0.37
PRKCI P41743 1/20 0.37
PRKCE Q02156 1/20 0.37
PRKCQ Q04759 1/20 0.37
PRKCZ Q05513 1/20 0.37
PRKCD Q05655 1/20 0.37
PRKD1 Q15139 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1046500 0.88 ZAP70 (0.57) ZAP70KCNH2CACNA1CASIC3MAP3K11
SCHEMBL1048255 0.80 ZAP70 (0.48) ZAP70EGFR
SCHEMBL1047173 0.76 ZAP70 (0.61) ZAP70
SCHEMBL1049666 0.75 ZAP70 (0.53) ZAP70
SCHEMBL1043375 0.73 ZAP70 (0.79) ZAP70
SCHEMBL1048263 0.73 ZAP70 (0.56) ZAP70
SCHEMBL1048423 0.73 ZAP70 (0.47) ZAP70
SCHEMBL1046812 0.72 ZAP70 (0.75) ZAP70
SCHEMBL1048684 0.71 ZAP70 (0.48) ZAP70
SCHEMBL1049082 0.70 ZAP70 (0.71) ZAP70EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US claimed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US claimed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FYN, SYK, RET ZAP70 4/4885KCNH2 1404/4885CACNA1C 2292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.